You are here: Home » Companies » News
Business Standard

Cipla, Boehringer Ingelheim to co-sell 3 oral anti-diabetic drugs in India

Pharma major Cipla and drug firm Boehringer Ingelheim India on Monday announced partnership to co-market three new oral anti-diabetic drugs in the country.

Cipla | Diabetes

Press Trust of India  |  New Delhi 

drug, medicine, pharmaceutical, pharma

Pharma major and drug firm Boehringer Ingelheim India on Monday announced partnership to co-market three new oral anti-diabetic drugs in the country.

The have entered into a partnership for co-marketing three new oral anti-diabetics drugs --- Oboravo (Empagliflozin),Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin) in India, and Boehringer Ingelheim India Pvt Ltd said in a statement.

As per the International Federation, India is home to 7.7 crore diabetic adults aged between 20-79 years, ranking second behind China, and is poised to reach 13.42 crore patients by 2045, it added.

"continues to be a focus area for and with a strategic partnership with Boehringer Ingelheim coupled with our strong brand building, patient access and reach capabilities, we will be at the forefront of providing holistic care," Cipla India Business Executive VP & CEO Nikhil Chopra said.

In a similar vein, Boehringer Ingelheim India MD Sharad Tyagi said: "As a dedicated organization to the field of diabetes, we aim to provide wider access and innovative solutions to the medical fraternity and patients with one of the most comprehensive diabetes portfolios in the country".

Oboravo is approved for glucose-control in patients with type-2 diabetes. It is also approved for reducing the risk of cardiovascular death, in patients with type-2 diabetes and established cardiovascular disease, it added.

While Oboravo Met can be given to newly diagnosed patients of type-2 diabetes who have higher baseline HbA1c levels, Tiptengio is the world's first approved combination of an SGLT-2 inhibitor and DPP4 inhibitor, the statement said.

Shares of Cipla Ltd were trading at Rs644.20 per unit on the BSE, up 1.50 per cent over previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, June 29 2020. 15:24 IST